Intraileal Glucose vs. Saline Infusion on Hormone Secretion and Glycemic Excursions

April 25, 2022 updated by: Sanyuan Hu, Qilu Hospital of Shandong University

Comparative Effects of Intraileal Glucose vs. Saline Infusion on Hormone Secretion and Glycemic Excursions in Subjects With Ileostomy

The distal ileum, where the glucagon-like peptide 1 (GLP-1) releasing cells predominate, is an important organ in mediating glycemic control. However, the distal ileum is not easy to access and the correspond in vivo research remains to be difficult. The investigators intend to recruit subjects who underwent rectal surgery with simultaneous protective ileostomy and evaluate hormone secretion and glycemic excursions via ileostomy glucose or saline infusion, and quantify the glucose absorption rate within the distal ileum.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Shandong
      • Jinan, Shandong, China, 250012
        • Qilu Hospital Of Shandong University
      • Jinan, Shandong, China, 250012
        • The First Affiliated Hospital Of Shandong First Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male and postmenopausal females aged 18 - 75 years
  • Body mass index (BMI) 20 - 35 kg/m2
  • With protective ileostomy due to benign or malignant rectal surgery

Exclusion Criteria:

  • History of postoperative adjuvant chemotherapy
  • Other significant illness, including epilepsy, cardiovascular or respiratory disease
  • Impaired renal or liver function (as assessed by calculated creatinine clearance < 90 mL/min or abnormal liver function tests (> 2 times upper limit of normal range))
  • Donation of blood within the previous 3 months
  • Participation in any other research studies within the previous 3 months
  • Females who are pre-menopausal
  • Inability to give informed consent
  • Vegetarians

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: patients with ileostomy without type 2 diabetes
intraileal glucose or saline infusion via ileostomy
intraileal glucose or intraileal saline infusion
Experimental: patients with ileostomy with type 2 diabetes
intraileal glucose or saline infusion via ileostomy
intraileal glucose or intraileal saline infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
serum or plasma GLP-1 changes during intraileal infusion
Time Frame: 180 minutes
concentration of serum or plasma GLP-1 (pmol/L)
180 minutes
serum or plasma GIP changes during intraileal infusion
Time Frame: 180 minutes
concentration of serum or plasma GIP (pmol/L)
180 minutes
serum or plasma ghrelin changes during intraileal infusion
Time Frame: 180 minutes
concentration of serum or plasma ghrelin (pg/ml)
180 minutes
serum or plasma c-peptide changes during intraileal infusion
Time Frame: 180 minutes
concentration of serum or plasma c-peptide (pmol/L)
180 minutes
serum or plasma insulin changes during intraileal infusion
Time Frame: 180 minutes
concentration of serum or plasma insulin (pmol/L)
180 minutes
serum or plasma glucagon changes during intraileal infusion
Time Frame: 180 minutes
concentration of serum or plasma glucagon (pmol/L)
180 minutes
glucose absorption capacity
Time Frame: 180 minutes
estimated glucose absorption rate during intraileal glucose infusion
180 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Kexin Wang, Qilu Hospital Of Shandong University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 22, 2021

Primary Completion (Actual)

March 1, 2022

Study Completion (Actual)

March 1, 2022

Study Registration Dates

First Submitted

August 23, 2021

First Submitted That Met QC Criteria

August 31, 2021

First Posted (Actual)

September 1, 2021

Study Record Updates

Last Update Posted (Actual)

April 26, 2022

Last Update Submitted That Met QC Criteria

April 25, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • QLYY-CRC-2020-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Incretins

Clinical Trials on intraileal infusion

3
Subscribe